Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate...
Eli Lilly’s Olumiant Patent Invalidated in China, Generic Version Approved
The China National Intellectual Property Administration (CNIPA) has declared the compound patent CN200980116857.7 for Eli...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
Tcelltech’s B7-H3 Targeting CAR-T Therapy TX103 Gets Tacit Clinical Approval for Glioblastoma
The Center for Drug Evaluation (CDE) website in China has indicated that Tcelltech’s TX103, a...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...
BriSTAR Immunotech’s LILRB4-Targeted Cell Therapy YTS104 Gets Tacit Approval for Clinical Trial in China
BriSTAR Immunotech, a clinical-stage cell therapy company based in Beijing, has received tacit clinical trial...
Biocytogen Launches RenBiologics Sub-brand to Expand Antibody Discovery Business
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced the launch...
Shanghai’s Reunion Biotech Secures Series B Funding to Advance Hydrogel Products
Reunion Biotech, a Shanghai-based medical hydrogel manufacturer, has reportedly secured nearly RMB 100 million (USD...
Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment
GenScipt Biotech Corp. (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), through its...
Beijing Sun-Novo and Zhejiang Anglikang Deepen Ties with New Drug Development Partnership
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has...
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001
Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a...
Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services
Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in...
J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth
Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for...
Establishment Labs Launches Motiva Breast Implants in China
Establishment Labs Holdings Inc., (NASDAQ: ESTA), a US-based medical technology company specializing in women’s health,...
Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...
Zylox-Tonbridge Medical Technology Secures NMPA Nod for Innovative Iliac Vein Stent System
Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...
Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China
The Center for Drug Evaluation (CDE) in China has indicated on its website that it...
Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...
Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...